NDA 206192 · Genentech INC
Cotellic
Cobimetinib Fumarate · Oral
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Aug 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Nov 10, 2015
Approved uses
4
Original approval plus efficacy supplements
Registered trials
115
10 Phase 3, 13 recruiting
FAERS reports
4,436
3,673 serious, 588 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 29, 2026.
COTELLIC ® is a kinase inhibitor indicated: For the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. ( 1.1 , 14.1 ) As a single agent for the treatment of adult patients with histiocytic neoplasms. ( 1.2 , 14.2 ) 1.1 Unresectable or Metastatic Melanoma COTELLIC ® is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. 1.2 Histiocytic Neoplasms COTELLIC®, as a single agent, is indicated for the treatment of adult patients with histiocytic neoplasms.
Mechanism: Cobimetinib is a reversible inhibitor of mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase 1 (MEK1) and MEK2. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation. BRAF V600E and K mutations result in constitutive activation of the BRAF pathway which includes MEK1 and MEK2. In mice implanted with tumor cell lines expressing BRAF V600E, cobimetinib inhibited tumor cell growth. Cobimetinib and vemurafenib target two different kinases in the RAS/RAF/MEK/ERK pathway. Compared to either drug...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 28, 2022 Supplement 5 · Efficacy · priority review OrphanLabelLetter
- Jul 28, 2022 Supplement 4 · Efficacy · priority review LetterLabel
- Jan 26, 2018 Supplement 2 · Efficacy LabelLetter
- Nov 10, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanSummary ReviewLetterLabel
1 products under this application
- COTELLIC · COBIMETINIB FUMARATE EQ 20MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cobimetinib" as an intervention, any sponsor and status, largest first.
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid TumorsPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT01928394 · 1,163 participants · Start Oct 24, 2013 · Primary completion Feb 5, 2019
Drug: Nivolumab; Ipilimumab and 1 more · For: Advanced or Metastatic Solid Tumors
Sites: Muscle Shoals, Alabama; Aurora, Colorado; New Haven, Connecticut · 38 sites in all
- A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02291289 · 1,044 participants · Start Apr 17, 2015 · Primary completion May 31, 2019
Drug: Cetuximab; FOLFOX induction regimen and 9 more · For: Colorectal Cancer
Sites: Buenos Aires, Argentina; La Rioja, Argentina; Viedma Rio Negro, Argentina · 154 sites in all
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03768063 · 1,000 participants (planned) · Start Feb 28, 2019 · Primary completion Jul 5, 2028
Drug: Atezolizumab; Bevacizumab and 14 more · For: Cancer
Sites: Aurora, Colorado; Trumbull, Connecticut; Boston, Massachusetts · 80 sites in all
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03178552 · 1,000 participants (planned) · Start Sep 22, 2017 · Primary completion Jun 30, 2027
Drug: Alectinib; Atezolizumab and 10 more · For: Non-Small Cell Lung Cancer
Sites: Sacramento, California; Denver, Colorado; Fort Myers, Florida · 161 sites in all
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolPivotal-lookingRecruiting
Cancer Research UKAcademic, hospital or other
NCT05722886 · 825 participants (planned) · Start Mar 1, 2023 · Primary completion Oct 2029
Drug: Alectinib; Atezolizumab and 5 more · For: Haematological Malignancy; Solid Tumour
Sites: Belfast, United Kingdom; Birmingham, United Kingdom; Bristol, United Kingdom · 27 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use482
- diarrhoea446
- rash402
- pyrexia368
- death253
- nausea235
- fatigue221
- vomiting185
- no adverse event183
- acute kidney injury139
- asthenia134
- photosensitivity reaction133
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 16 |
| 2014 | 26 |
| 2015 | 86 |
| 2016 | 455 |
| 2017 | 583 |
| 2018 | 706 |
| 2019 | 556 |
| 2020 | 370 |
| 2021 | 362 |
| 2022 | 342 |
| 2023 | 239 |
| 2024 | 368 |
| 2025 | 194 |
| 2026 | 131 |
Recalls
1 FDA enforcement reports for this application.
Mar 13, 2017 · Class II · Terminated
Superpotent Drug: An oversized tablet was found in a bottle.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cotellic (Cobimetinib Fumarate)
2024 spending
$8.2M
Beneficiaries
250
1,518 claims
Per beneficiary
$32,649
$124.35 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,152,986 |
| 2021 | $5,315,892 |
| 2022 | $5,979,372 |
| 2023 | $6,345,616 |
| 2024 | $8,162,277 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.
Brastianos PK, Twohy E, Geyer S, et al. · N Engl J Med 2023 · Clinical Trial, Phase II, Research Support, U.S. Gov't, P.H.S.
- Efficacy of MEK inhibition in patients with histiocytic neoplasms.
Diamond EL, Durham BH, Ulaner GA, et al. · Nature 2019 · Clinical Trial, Research Support, N.I.H., Extramural
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Eng C, Kim TW, Bendell J, et al. · Lancet Oncol 2019 · Clinical Trial, Phase III, Multicenter Study
- Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial.
Cabanillas ME, Dadu R, Ferrarotto R, et al. · JAMA Oncol 2024 · Clinical Trial, Phase II, Research Support, N.I.H., Extramural
- Systemic Therapy for Melanoma: ASCO Guideline.
Seth R, Messersmith H, Kaur V, et al. · J Clin Oncol 2020 · Practice Guideline, Systematic Review
- A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma.
Buchbinder EI, Giobbie-Hurder A, Haq R, et al. · Invest New Drugs 2023 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.